Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Minimal alveolar concentration of sevoflurane in renal transplant patients
2015-003141-25Phase 4Terminated
- Sponsor
- Medical University of Vienna
- Start
- Aug 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, single-arm trial of sevoflurane in end-stage kidney disease (ESKD), sponsored by Medical University of Vienna. Primary endpoint: Minimal alveolar concentration (MAC) of sevoflurane. Started Aug 2015; status: terminated.
02
Drugs
sevoflurane
03
Conditions
end-stage kidney disease (ESKD)
Beyond the preview
Go deeper on 2015-003141-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-003141-25.